In short
Clinical trials are investigating ALN-961583 in people with cerebral amyloid angiopathy, a brain blood vessel condition linked to bleeding. These studies aim to evaluate efficacy, safety, and tolerability in adults with this condition.
Key points
- Clinical trials of ALN-961583 are studying adults with cerebral amyloid angiopathy, a condition where amyloid proteins build up in brain blood vessel walls. The trial is Phase 2 and is designed to assess efficacy, safety, and tolerability. Researchers are especially looking at the annualized rate of new lobar cerebral microbleeds on MRI. The study is authorised and plans to enroll 200 participants. The trial uses an interventional design and compares ALN-961583 with placebo.
Trial overview
The available trial for ALN-961583 is an interventional study, which means researchers give a study treatment and compare the results with another group. It is listed as Phase 2, a stage that is used to learn more about whether a treatment may work and how safe it is in the target group. The trial status is Authorised, and the planned enrollment is 200 patients.
Condition studied: cerebral amyloid angiopathy
The study focuses on cerebral amyloid angiopathy (CAA), a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain. This buildup can cause problems such as bleeding into the brain.
The trial description also refers to CAA as a condition linked to lobar cerebral microbleeds, which are small bleeding spots in the outer parts of the brain. The study is especially interested in patients with symptomatic CAA, written in the source as sCAA.
Study design and treatment groups
The trial compares ALN-961583 with placebo, which is a look-alike treatment with no active medicine. The intervention list in the source names Mivelsiran and placebo, with Mivelsiran given by intrathecal use, meaning it is delivered into the fluid around the spinal cord.
The brief summary says the study is designed to evaluate the effect of ALN-APP on the incidence of new lobar cerebral microbleeds. In patient-friendly terms, the researchers want to see whether the study treatment changes how often new small bleeding spots appear on brain scans.
Who can participate
The target population is patients with cerebral amyloid angiopathy. The source does not provide more detailed eligibility rules, such as age limits or other medical requirements.
Because this is a study in people with CAA, participation is aimed at adults who already have this condition or are being evaluated for it, based on the trial setting described in the source.
What the trial measures
The primary outcome is the annualized rate of new lobar cerebral microbleeds detected by MRI in patients with CAA. A primary outcome is the main result the study is built to measure.
MRI stands for magnetic resonance imaging, a scan that makes detailed pictures of the brain. In this trial, MRI is used to count new microbleeds over time, which helps researchers track whether the study treatment changes brain bleeding activity.
Why this trial matters
This study is important because CAA can be linked to brain bleeding, and new microbleeds are one sign of ongoing disease activity. By measuring both safety and the rate of new microbleeds, the trial aims to give a clearer picture of whether ALN-961583 may be useful for this condition.
The trial is still in a mid-stage testing phase, so it is focused on learning more rather than proving final effectiveness. The results may help guide later research in people with CAA.